Brian Rudolph Shy

This study engineers primary human T cells to deliver gene editing machinery using retroviral-based delivery vehicles, demonstrating efficient editing of diverse target cells.

This paper develops a virus-like particle-based system for CRISPR gene editing and screening in primary human myeloid cells, identifying TNFAIP3 as a key regulator of inflammatory polarization.

This paper develops a non-viral BCMA CAR-T therapy using CRISPR and 1XX signaling, showing improved safety, potency, and persistence in multiple myeloma.

This paper identifies methods to achieve ultra-large DNA integrations (>10 kb) in human cells with high efficiency using optimized templates and delivery strategies.

This paper introduces Hybrid Receptors (Hybrid-Rs) to improve T cell therapy safety and programmability by combining CAR and SNIPR features for controlled gene regulation and reduced toxicity.

The paper investigates DNA repair in postmitotic neurons and shows that manipulating repair pathways can influence CRISPR editing outcomes.

This paper engineers CCL27 mutants to enhance CAR T-cell efficacy against multiple myeloma by targeting CCR10, achieving results comparable to BCMA CAR-Ts.

The paper identifies JCV VP1 epitopes recognized by HLA-A2 and isolates TCRs that recognize these epitopes, showing cytotoxic activity against infected cells.

This study introduces CRISPRai, a bidirectional epigenetic editing system, to investigate gene regulation hierarchies and interactions in T cells and hematopoietic lineage transcription factors.

This paper describes an engineered E. coli strain that produces long single-stranded DNA efficiently, validated for use in genome editing and DNA origami.

This paper develops a method to efficiently reprogram T cells at multiple loci using SEED-Selection, achieving high purity for single and combined gene edits.

The paper develops a non-viral method using hybrid ssDNA repair templates to improve genome engineering in primary human cells, achieving high knock-in efficiency and cell yields for disease modeling and cell therapy.